Mankind Pharma shares jumped nearly 8% on Tuesday to an intraday high of Rs 2,500 on the NSE after the company reported a 38% year-on-year rise in Q2 profit after tax (PAT) to Rs 716 crore, while revenue grew 17% over the same period.
According to an exchange filing, the company posted a 37.7% rise in profit to Rs 716 crore in the September quarter, from Rs 520.2 crore in the year-ago period, driven by strong business growth in domestic and international markets.
Also Read | Mankind Pharma Q2 profit rises 38% to Rs 716 crore
Revenue from operations rose to Rs 4,337.9 crore during the quarter under review, compared with Rs 3,697.2 crore in the year-ago period, registering a 17.3% growth. Domestic revenue stood at Rs 3,657 crore, registering a jump of 14.8%, while exports stood at Rs 681 crore, up 32.7% year-on-year.
EBITDA was recorded at Rs 1,175 crore, up from Rs 924 crore in Q2FY26. The EBITDA margin stood at 27.1%, up 210 bps year-on-year, while the PAT margin stood at 16.5%, up 240 bps YoY.
“Our disciplined execution and strengthening business fundamentals resulted in strong performance. Our recent acquisition of Armed Cell Therapeutics marks strategic entry into Next-Generation CAR-T therapies, strengthening R&D capabilities for future growth,” said Rajeev Juneja, Vice Chairman & Managing Director.
Domestic business
The domestic pharmaceutical business, excluding consumer healthcare, grew 15.9%, driven by strong performance in both chronic and acute therapies. Cardiac therapies recorded growth of around 19%, while anti-diabetes products grew 16%. Meanwhile, the company’s international business expanded 33%, while OTC witnessed muted growth in Q2.
The company also highlighted that it has consistently maintained its number one rank over the last nine years, with a prescription share of 15.2% and prescriber penetration of 84.4% in MAT Aug’26. Secondary sales grew 15.7%, exceeding the Indian Pharmaceutical Market’s (IPM) growth of 14.2% and representing 1.1 times the market’s growth rate.
Consumer healthcare business
Revenue growth was impacted by slower offtake in the industry category and some regional impact in the East and South. Despite softer growth, the company gained market share in key brands, Manforce and Preganews. The MT & E-Com share increased to 18% in Q2FY27, compared with 12% in Q2FY26, supported by 55% growth.
Exports
International revenue increased by 33% in Q2FY27, driven by strong growth in both Mankind and BSV International. The company launched 1 new product in Q2FY27, taking the total number of products launched in the US to 50.
In its exchange filing, the company said that revenue from operations in the first half of FY27 stood at Rs 8,368 crore, up 15.1% YoY. Domestic revenue stood at Rs 7,082 crore, up 12.7%, while exports stood at Rs 1,286 crore, up 31.0% YoY.
Also Read | Mankind Pharma shares key business developments from Q2 & H1 of FY27
During the same period, the EBITDA margin stood at 26.7%, up 230 bps YoY, while the PAT margin stood at 15.4%, up 210 bps YoY. Diluted EPS stood at Rs 30.9, up 34.6% YoY (FV Re 1).
Mankind Pharma share price movement
Over the last one week, the stock gained 10.58% and was marginally up by 0.68% over the last one month. So far in 2026, the stock has gained 15.11%. Shares of Mankind Pharma were up 3.10% over the last one year and nearly 41.67% over the last three years.
Disclosure: This article has been written by Surbhi Khanna, who is not a SEBI-registered Research Analyst or an investment advisor. Surbhi Khanna does not hold any financial interest in Economic Times as of the date of publication. The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of the EconomicTimes Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment.